Health News
Drug combination shows meaningful responses for malignant peritoneal mesothelioma patients
07/22/2021
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in
Read More
